-- Expanded strategic partnership with Kite -- -- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory multiple myeloma -- -- Ended the quarter with $729.2M, extending cash runway into 2027 -- REDWOOD CITY, Calif., Feb. 28, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other ...

Following a hot year of M&A with biotech stocks, we’ll see more of the same in 2024 as drug makers look to build their pipelines ahead of a massive patent cliff. Between now and 2028, pharmaceutical giants stand to lose billions in revenue as blockbuster drug patents expire. According to EY analysts, the top 20 pharmaceutical giants could lose about $180 billion in sales by the end of the decade. It’s part of the reason Johnson & Johnson (NYSE:JNJ) said it would acquire antibody-drug conjugate (ADC) company ...

Industry Overview - Biotech stocks have faced significant challenges over the past two years due to reduced venture capital, shifts in the healthcare landscape post-pandemic, and tighter regulatory environments, but 2024 may signal a recovery for the sector [1] - The FDA approved 50% more novel therapeutics in 2023 compared to 2022, with a total of 55 treatment protocols approved, indicating a potential resurgence in biotech stock performance [1] Regeneron Pharmaceuticals (REGN) - Regeneron Pharmaceuticals has demonstrated consistent stock performance, with a low beta of 0.16, indicating stability even during economic turmoil [2] - The company received FDA approval in August 2023 for a high-dosage variant of its eye disease therapeutic Eylea, enhancing its competitive position against price negotiations from Medicare [2] - Regeneron's flagship drug Dupixent is being tested for chronic obstructive pulmonary disease (COPD), showing a 34% decrease in symptoms, with potential annual sales reaching $20 billion if successful [3] - The company is actively developing compounds in high-interest areas such as monoclonal antibody therapeutics, gene therapy, and gene editing [3] Arcellx Inc (ACLX) - Arcellx is focused on cancer and autoimmune disease treatments, particularly through CAR-T therapeutics, which utilize the patient's immune system to combat cancer [5] - The company has secured significant financial backing from Gilead Sciences, including an $85 million cash payment and a $200 million stock purchase plan, ensuring operational stability through 2027 [6] Beam Therapeutics (BEAM) - Beam Therapeutics is engaged in gene therapy and editing, with a focus on sickle cell treatments, currently in testing stages [7] - The company anticipates significant developments in 2024, supported by a robust cash position of approximately $1.2 billion, allowing for sustained operations through 2027 [8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-41259 ARCELLX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-2855917 (State or other ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-41259 ARCELLX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-2855917 (State or other jurisdi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-41259 ARCELLX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-2855917 (State or other jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41259 ARCELLX, INC. (Exact name of Registrant as specified in its Charter) Delaware 47-2855917 (State or other jurisdiction of (I.R.S ...

Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on our management’s beliefs and assumptions and on information currently available to our management. All statements other than statements of historical facts contained in this presentation, including statements regarding the anticipated 3202 comple ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Common Stock, $0.001 par value per share ACLX The Nasdaq Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-41259 | --- | --- | --- | --- | |-- ...